# Antiangiogenic Effect of Alkaloids

Authors: Masoud Alasvand; Vahideh Assadollahi; Roberto Ambra; Ehsan Hedayati; Wesam Kooti; Ilaria Peluso
Journal: Oxidative Medicine and Cellular Longevity
 (2019)

---

## Abstract

Alkaloids are among the natural phytochemicals contained in functional foods and nutraceuticals and have been suggested for the prevention and/or management of oxidative stress and inflammation-mediated diseases. In this review, we aimed to describe the effects of alkaloids in angiogenesis, the process playing a crucial role in tumor growth and invasion, whereby new vessels form. Antiangiogenic compounds including herbal ingredients, nonherbal alkaloids, and microRNAs can be used for the control and treatment of cancers. Several lines of evidence indicate that alkaloid-rich plants have several interesting features that effectively inhibit angiogenesis. In this review, we present valuable data on commonly used alkaloid substances as potential angiogenic inhibitors. Different herbal and nonherbal ingredients, introduced as antiangiogenesis agents, and their role in angiogenesis-dependent diseases are reviewed. Studies indicate that angiogenesis suppression is exerted through several mechanisms; however, further investigations are required to elucidate their precise molecular and cellular mechanisms, as well as potential side effects.


---

## Body

## 1. Introduction

Alkaloids are among the natural phytochemicals contained in functional foods and nutraceuticals [1] and have been suggested for the prevention and/or management of oxidative stress and inflammation-mediated diseases [1, 2]. In this review, we aimed to describe the effect of alkaloids on angiogenic vessel formation from a previous existing capillary, a process that is implicated in many physiological conditions such as wound healing and menstrual cycle and pathological conditions such as tumor growth or retinopathy [3–5].The angiogenic process is a cascade of events resulting in new lumen-containing vessels, through the dissolution of the vascular basal membrane, migration of endothelial cells from the parent vessel toward developing blood vessels, and widespread cellular proliferation, which are activated by several proangiogenic factors. When blood flow is initiated, physiological processes such as embryonic development, wound healing, and immune reactions are then allowed to start and develop [6, 7]. On the other hand, the creation of new blood vessels increases the supply of nutrients, oxygen, and growth factors to normal and tumor cells. If tumor cells can induce angiogenesis, subsequent tumor expansion and transition from a benign state to a malignant one is started [8]. Endothelial cells can migrate in order to initiate or progress to angiogenesis, thanks to a wide range of regulators and signaling molecules such as basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and transforming growth factor (TGF). Thus, these angiogenic peptides play a critical role in the creation of new blood vessels [9–11]. In both physiological and pathological conditions, HIF-1 is a critical mediator of hypoxic response and O2 homeostasis as well as an essential angiogenic regulator. Hypoxia leads to HIF-1α stabilization, a subunit of the heterodimeric transcription factor HIF-1, and increased VEGF production [12, 13]. Oxygen demand can be increased by excessive cell proliferation during embryonic development and/or tumor growth [14].Moreover, VEGF is the main factor that initiates angiogenesis. Similar to some proangiogenic genes, VEGF also has hypoxia response element (HRES) as the binding site of HIF-1 within the promoters. In hypoxic conditions, HIF-1 directly stimulates VEGF and its receptors, inducing angiogenesis [15, 16]. The abovementioned mechanisms in the formation of new blood vessels demonstrate that VEGF directly links hypoxia with angiogenesis initiation. The VEGF family of growth factors exerts its effects by interacting with receptor tyrosine kinases (RTKs) named vascular endothelial growth factor receptors (VEGFRs). Activation of this signaling pathway leads to endothelial cell (EC) proliferation, extracellular matrix degradation, EC migration, and then new blood vessel formation [17, 18]. Understanding the tumor angiogenesis signaling pathways is an important treatment goal of malignancy and cancer therapy. However, because of the similarities between tumor and physiologic angiogenesis signaling pathways, insufficient efficacy and resistance may be challenges we face during such cancer therapy [19].The results of different studies show that several molecular pathways such as VEGFRs, Ephrin-Eph receptors, and the Delta-like ligand and neurogenic locus notch homolog protein (Delta-Notch) system are involved in angiogenesis [7, 20].


## 2. Angiogenesis Signaling Pathways

VEGF belongs to the platelet-derived growth factor (PDGF) family; moreover, the VEGF family has five members in mammals, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF (placental growth factor). All of them stimulate cellular responses and are characterized by the presence of eight conserved cysteine residues forming the typical cysteine-knot structure [21]. VEGFRs are tyrosine kinase receptors (TKRs) with a cytoplasmic domain and tyrosine kinase activity, containing 3 to 4 members. VEGF-A, the most important member of this family, was obtained from tumor cells for the first time. VEGF-A regulates angiogenesis and vascular permeability via activation of VEGFR-1 and VEGFR-2. The binding of VEGF-A to its receptor represents the most important signal for angiogenesis. On the other hand, VEGF-C/VEGF-D and their receptor, VEGFR-3, are involved in lymphangiogenesis [22, 23]. Several VEGF family ligands and receptors, especially VEGF-A, are regulated by HIF; therefore, angiogenesis is intensified during healthy tissue growth and also in cancerous conditions [24]. Following the binding of VEGF-A to VEGFR2, the RAS/RAF (rapidly accelerated fibrosarcoma)/ERK (extracellular signal-regulated kinases)/MAPK (mitogen-activated protein kinases) pathway is activated potentially via sphingosine kinase (SPK) activated by protein kinase C (PKC). RAS target genes can now be enabled, inducing proliferation [25]. Recent studies consider the role of the transcription factor nuclear factor-kappa beta (NF-κB), which interacts with RAS, in tumor angiogenesis; therefore, it can be an antiangiogenic therapeutic target. It has been demonstrated that oncogenic RAS mediates the activation of the NF-κB pathway and subsequent upregulation of NF-κB target genes, in particular the proangiogenic IL-8 cytokine, leading to lung tumorigenesis [26].Other RAS-independent molecular pathways, such as the phospholipase C gamma- (PLCγ-) protein kinase C- (PKC-) MAPK pathway, are also implicated in VEGFR2 signaling [22]. Binding of VEGFR2 to VEGF-A and phosphorylation of several tyrosine residues in the cytoplasmic domain of this receptor can induce the activation of phospholipase C gamma (PLCγ). On the one hand, PLCγ releases diacylglycerol (DAG) which recruits PKC to the cell membrane and promotes cell proliferation; on the other hand, PLCγ-mediated Ca2+ mobilization leads to increased vascular permeability, promoting leakage of plasma proteins into the extravascular space, resulting in a fibrin gel formation marking the proper temporary place for the placement of the new blood vessel, and supporting its growth [23, 27, 28].Generally, the phosphorylation of different tyrosines in the cytoplasmic domain of VEGFR2 and the subsequent recruitment of signal transducers promote migration and cell mobility and regulate cell attachment, all of which are needed for angiogenesis [29]. As already mentioned, different molecular pathways are involved in pathophysiological angiogenesis compared to the physiological one [30]. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is activated in many human cancers. The activation of the PI3K/AKT pathway in cancer cells can increase VEGF production. This may be done through HIF-1-dependent mechanisms, or it may occur in an HIF-1-independent manner. In tumor cells, PI3K/AKT activation can occur because of RAS mutation which is responsible for tumor cell feeding [12]. Other signaling pathways, such as JAK-STAT, can promote the migration of endothelial cells and subsequent tumor angiogenesis [31].On the other hand, VEGFR1 is a negative regulator of angiogenesis. VEGFR1 is a decoy receptor, and the binding of VEGF-A to it may prevent the activation of VEGFR2. Also, Delta-like ligand 4 (DII4), a transmembrane ligand of notch family receptors, is a negative regulator of angiogenesis. More precisely, when VEGF binds to VEGFR2, it causes DII4 upregulation which in turn interacts with NOTCH1 receptors on adjacent endothelial cells, resulting in VEGFR2 downregulation in those cells. Finally, the activation of Notch signaling leads to a reduced number of tip cells and less dense vascular network formation via the prevention of tubular sprouting in angiogenesis [22, 32].The involvement of coagulation factors in tumor-induced and normal angiogenesis has been reported in several studies [33, 34], supporting their role in tumor progression.


## 3. Angiogenesis Inhibitors and Cancer Treatment

Angiogenesis is the creation of new capillaries from preexisting vessels and circulating endothelial precursors [35]. It can be activated in physiological and pathological conditions, for example, in response to hypoxia, cancer, diabetic retinopathy, and inflammatory, infectious, and immune disorders [36]. Proangiogenic growth factors commonly switch on a series of surface receptors in a series of paracrine and autocrine circles with the VEGF-A signaling representing the critical rate-limiting step, physiologically and pathologically. VEGF-A is the main VEGF that binds to VEGFR2 to mediate vascular permeability, endothelial proliferation, migration, and survival [37].Angiogenesis also plays a critical role in the growth of cancer for the reason that cancer tissues need a blood supply. Tumors can stimulate normal cells to generate angiogenesis signaling molecules. Angiogenesis inhibitors act through several ways. Some of them are monoclonal antibodies that recognize and bind to VEGF. When VEGF is attached to these drugs, it is unable to activate the VEGF receptor [38].Other inhibitors bind to the VEGF receptor on the surface of endothelial cells or to other proteins in the downstream signaling pathways and block their activities. Some of the inhibitors are immunomodulatory drug agents that stimulate or suppress the immune system. One of the ideas of antiangiogenic therapy is through the destruction tumor vessels [39].Since angiogenesis is the main requisite for cancer growth and invasion, its inhibition is considered the mainstay in cancer treatment strategies. The study of angiogenesis led to the identification of numerous proangiogenic factors as well as angiogenic suppressor proteins. By the identification of these proteins, a wide spectrum of angiogenesis inhibitors were introduced in cancer treatment procedures. Several antiangiogenic molecules currently in use employ anti-VEGF-A antibodies [40, 41] and tyrosine kinase inhibitors [42–45]. However, serious adverse effects have been reported for such molecules [46]. On the other hand, herbal drugs, most commonly alkaloid-based plants, are among the more promising angiogenic inhibitors to be used for the treatment of different types of cancers like prostate cancer cells, breast cancer cells, melanoma cells, and cervical cancer cells [47–51].


## 4. Role of MicroRNAs in Angiogenesis Regulation

The identification of proteins involved in angiogenic processes led to the identification of microRNAs (miRNAs) as potent inhibitors of angiogenesis and cancer. MiRNAs are single-stranded short noncoding RNA molecules (about 21-25 nucleotides) that modulate cellular target genes at the posttranscriptional level. These RNA molecules have a role in almost all biological processes and their potential role in most pathogenesis has been observed. Cancers and thrombotic and bleeding disorders, as well as heart disease, are among those disorders in which the potential role of miRNAs has been investigated. Defects in miRNA synthesis led to a wide spectrum of early disorders including impaired T-cell formation, cardiomyopathy, disrupted blood circulation, and impaired angiogenesis [52–55]. One of the most important consequences of the impaired biogenesis of miRNAs is early embryonic lethality due to defective vessel formation and maintenance [56–58]. These observations encouraged studies to evaluate the role of different miRNAs in angiogenic processes, and several miRNAs were identified with a potential role in the regulation of different aspects of angiogenesis.It has been reported that some of the miRNAs, such as miR-126, miR-221/222, miR-17-92 cluster, miR-93, let-7f, and miR-214, modulate the response of the vascular endothelium to angiogenic stimuli and can be proangiogenic or antiangiogenic [59–62].MiR-221 and miR-222 are two relatively well-known miRNAs with an important effect on protooncogene c-Kit (CD117) as a key role in thesurvival of hematopoietic stem cells. Further studies on endothelial cells revealed that these two miRNAs have antiangiogenic activity [63, 64]. Overexpression of miR-221 and miR-222 in endothelial cells led to increased endothelial nitric oxide synthase, which in turn resulted in the suppression of endothelial survival and angiogenesis. MiR-34a is another miRNA with potential antiangiogenic activity, as it was shown to induce endothelial progenitor cell (EPC) senescence and dysfunction. EPCs have a crucial role in angiogenesis and are important for many physiological processes, even pathological ones, such as the growth of tumor cells [65, 66]. MiR-34a suppresses silent information regulator 1 (Sirt1) resulting in senescence induction in EPCs [67]. Mir-126 is another miRNA with direct and indirect effects on angiogenesis that is mainly found in tissues with high vascular components, such as the lungs and the heart [68–70]. MiR-126 regulates many endothelial cell functions and processes mainly including cell migration and cell survival. MiR-93 is involved with the stimulation of angiogenesis and the promotion of tumor growth, and its inhibition is suggested as a tool for the suppression of angiogenesis and tumor growth [71, 72].Endothelial cells express VEGF receptor genes. miRNAs can modulate angiogenesis by regulating VEGF receptor expression in endothelial cells, whereupon they influence the migration and invasion of cancer cells. In addition, recent studies showed that Dicer and Drosha, two enzymes that control the processing of miRNAs, play key roles in the angiogenic process. Not only do miRNAs modulate mRNA translation level, but mRNA also regulates the function of miRNAs. Thus, researchers can target the molecular pathways, taking part in the development of diseases, by determining miRNAs which are important in the angiogenic process [57, 59, 73, 74].The number of known miRNAs with a direct or indirect role in angiogenesis is on the rise, and a summary is shown in Table1.Table 1
Effect of different microRNAs on the angiogenic process.
MiRNA
Target gene
Role
Function
Reference
MiR-34a
Silent information regulator 1 (Sirt1)
MiR-34a has been found to target silent information regulator 1 (Sirt1), leading to cell cycle arrest or apoptosis
Antiangiogenesis
[67]
MiR-107
HIF-1β
MiR-107 decreases hypoxia signaling by suppressing expression HIF-1β
Antiangiogenesis
[75]
MiR-132
p120RasGAP
MiR-132 acts as an angiogenic switch by targeting p120RasGAP in the endothelium and thereby inducing neovascularization
Angiogenesis
[76]
MiR-424
Cullin 2 (CUL2)
MiR-424 targeted Cullin 2 (CUL2), a scaffolding protein critical to the assembly of the ubiquitin ligase system, thereby stabilizing HIF-α isoforms
Angiogenesis
[77]
MiR-93
Integrin-β8
MiR-93 promotes angiogenesis by suppressing integrin-β8 expression
Angiogenesis
[71]
MiR-29b
MMP-2
MiR-29b exerted its antiangiogenesis function, at least partly, by suppressing MMP-2 expression in tumor cells
Antiangiogenesis
[78]
MiR-519c
HIF-1α
Overexpression of miR-519c resulted in a significant decrease of HIF-1α protein levels and reduced the tube formation of human umbilical vein endothelial cells
Antiangiogenesis
[79]
MiR-210
VEGF and VEGFR
Overexpression of miR-210 enhances VEGF and VEGFR2 expression and promotes angiogenesis
Angiogenesis
[80]
MiR-155
Von Hippel-Lindau (VHL)
MiR-155 has a pivotal role in tumor angiogenesis by downregulation of VHL
Angiogenesis
[81]
MiR-195
VEGF, VAV2, CDC42
MiR-195 directly inhibited the expression of the proangiogenic factor VEGF and the prometastatic factors VAV2 and CDC42
Antiangiogenesis
[82]
MiR-145
HIF-2α
MiR-145 suppressesHIF-2α expression, thus inhibiting the angiogenesis
Antiangiogenesis
[83]
MiR-26a
HGF-hepatocyte growth factor receptor (cMet)
MiR-26a exerted its antiangiogenesis function, at least in part, by inhibiting HGF-hepatocyte growth factor (cMet) and its downstream signaling pathway
Antiangiogenesis
[84]
MiR-214
Hepatoma-derived growth factor (HDGF)
Downregulation of miR-214 contributes to the unusual hypervascularity of HCC via activation of the HDGF paracrine pathway for tumor angiogenesis
Antiangiogenesis
[85]
MiRNA-24
eNOS
Inhibition of microRNA-24 improves reparative angiogenesis in myocardial infarction
Antiangiogenesis
[86]
MiR-29a
Phosphatase and tensin homolog (PTEN)
TGF-β-regulated miRNA in promoting angiogenesis by targeting PTEN to stimulate AKT activity
Angiogenesis
[87]
MiR-27b
Vascular endothelial growth factor C (VEGFC)
MiRNA-27b targets vascular endothelial growth factor C to inhibit angiogenesis in colorectal cancer
Antiangiogenesis
[88]
MiR-503
FGF2 and VEGF-A
Demonstrate the antiangiogenesis role of miR-503 in tumorigenesis and provide a novel mechanism for hypoxia-induced FGF2 and VEGF-A through HIF1α-mediated inhibition of miR-503
Antiangiogenesis
[89]
MiR-143
Insulin-like growth factor-I receptor (IGF-IR)
Overexpression of miR-143 inhibited cell proliferation, migration, tumor growth, and angiogenesis and increased chemosensitivity to oxaliplatin treatment in an IGF-IR-dependent manner
Antiangiogenesis
[90]
MiR-382
Phosphatase and tensin homolog (PTEN)
MiR-382 induced by hypoxia promotes angiogenesis and acts as an angiogenic oncogene by repressing PTEN
Angiogenesis
[91]
MiR-210
Vascular endothelial growth factor (VEGF)
MiR-210 is a key factor at the microRNA level in promoting angiogenesis and neurogenesis, which was associated with local increased vascular endothelial growth factor (VEGF) levels
Angiogenesis
[92]
MiR-542-3p
Angiopoietin-2 (Angpt2)
MiR-542-3p inhibited translation ofAngpt2 mRNA by binding to its 3′ UTR, and the addition of miR-542-3p to cultured endothelial cells attenuated angiogenesis
Antiangiogenesis
[93]
MiR-214
Quaking
MiR-214 directly targets Quaking, a protein critical for vascular development. Quaking knockdown reduced proangiogenic growth factor expression and inhibited endothelial cell sprouting similar to miR-214 overexpression
Antiangiogenesis
[94]
MiR-20a
p300
P300 drives an angiogenic transcription program during hypertrophy that is fine-tuned in part through direct repression of p300 by miR-20a
Antiangiogenesis
[95]
MiR-15a
FGF2 and VEGF
MiR-15a negatively regulates angiogenesis in vivo and in vitro by suppression of FGF2 and VEGF
Antiangiogenesis
[96]


## 5. Plant-Based Alkaloids

Nowadays, a wide variety of plants that are rich in alkaloids have been discovered and these compounds have a significant impact on angiogenesis-dependent diseases. Alkaloids have an antiangiogenic activity and act through several mechanisms inhibiting angiogenesis. There are many alkaloids, but this review takes into account only the most important ones. By considering the hypothetical amino acid precursors and origins, different plant-based alkaloids in use are sorted into different groups. Table2 summarizes the different alkaloids.Table 2
Classification of different alkaloids based on amino acid precursors and their origins.
Amino acid precursors
Tyrosine
Tryptophan
Lysine
Alkaloid origins
Berberine
Brucine
Matrine
Hydrastis canadensis; Coptis chinensis
Strychnos nux-vomica L.
Sophora alopecuroides
Noscapine
Evodiamine
Capsaicin
Papaver somniferum L.
Evodia rutaecarpa
Capsicum annum L.
Sanquinarine
Homoharringtonine
Halofuginone
Sanquinaria canadenis L.
Cephalotoxus
Dichroa febrifugus
Sinomenine
Pterogynidine
Sinomenium acutum
Pterogyne nitens Tul
Taspine
Tetrandarine
Stephania tetrandra S.Table3 summarizes studies that evaluated the effect of different alkaloids on angiogenesis in different types of disorders.Table 3
Effects of different alkaloids on angiogenesis.
Name of alkaloid
N
Molecules
Biological results
Sample type
Year
Author
Noscapine
1
HIF-1
Decrease
Inhibit angiogenesis by downregulating VEFG
U87MG and T98G cell lines
2006
Newcomb et al. [97]
2
VEGF
Decrease
Inhibit angiogenesis
Human T98 cell lines
2008
Newcomb et al. [98]
3
VEGF
Decrease
Inhibit angiogenesis
Murine GL261 glioma cell lines
2008
Newcomb et al. [98]
4
MMP-9VEGF
Decrease
Inhibit angiogenesis
KBM-5, HL-60, Jurkat, HuT-78, U266, RPMI- 8226, H1299, A293, DU145, and SCC4 cell lines
2010
Sung et al. [99]
5
VEGF
Decrease
Inhibit angiogenesis
The A549 or H460 cell
2010
Chougule et al. [100]
6
VEGF
Decrease
Inhibit angiogenesis
Xenografted with H460 tumors (mice)
2010
Chougule et al. [100]
7
HIF
Decrease
Inhibit angiogenesis
Ovarian cancer cells
2011
Su et al. [101]
8
NFKBVEGF
Decrease
Inhibit angiogenesis
The human breast cancer cell lines MDA-MB-231 and MDA-MB-468
2011
Chougule et al. [100]
Berberine
9
HIF-1
Decrease
Inhibit angiogenesis by downregulating VEGF
Gastric adenocarcinoma cell line SC-M1
2004
Lin et al. [102]
10
VEGF
Decrease
Inhibit angiogenesis
HeLa cell
2008
Lin et al. [103]
11
VEGFMMP-2
Decrease
Inhibit angiogenesis
Human umbilical vein endothelial cells
2009
Gao et al. [104]
12
Mmp-2/9UPA
Decrease
Inhibit angiogenesis
Squamous cancer cell
2009
Ho et al. [105]
13
VEGF
Decrease
Inhibit angiogenesis
Hepatocellular carcinoma
2010
C. Cheung et al.
14
VEGF
Decrease
Inhibit angiogenesis
Hep G2 cell line
2011
Jie et al. [106]
15
HIF-1VEGF
Decrease
Inhibit angiogenesis
B16F-10 melanoma cells and C57BL/6 mice
2012
Hamsa and Kuttan [107]
16
VEGF
Decrease
Inhibit angiogenesis
Xenografted hepatocellular carcinoma (mice)
2012
Ruhua [108]
17
VEGF
Decrease
Inhibit angiogenesis
Hepatocellular carcinoma
2012
Wang et al.
18
VEGF
Decrease
Inhibit angiogenesis
Breast cancer
2013
Kim et al. [109]
19
VEGF
Decrease
Inhibit angiogenesis
HepG2 cells
2013
Wang and Ke [110]
20
VEGF
Decrease
Inhibit angiogenesis
Human non-small-cell lung cancer
2013
Fu et al. [111]
21
Mmp-2UPA
Decrease
Inhibit angiogenesis
Cervical cancer
2014
Chu et al.[112]
22
VEGF
Decrease
Inhibit angiogenesis
Hepatocellular carcinoma
2015
Tsang et al. [113]
Sanguinarine
23
VEGF
Decrease
Inhibit angiogenesis
Swine granulosa cell
2006
Bianco et al. [114]
24
VEGF
Decrease
Inhibit angiogenesis
Endothelial cell line
2007
Basini et al. [115]
25
VEGF
Decrease
Inhibit angiogenesis
Swine granulosa cells
2007
Basini et al. [116]
26
VEGF
Decrease
Inhibit angiogenesis
Porcine aortic endothelial cell line
2007
Basini et al. [117]
27
VEGF
Decrease
Inhibit angiogenesis
Swine ovarian follicles
2008
Basini et al. [116]
28
?
?
Inhibit angiogenesis
B16 melanoma 4A5 cells
2009
De Stefano et al. [118]
29
VEGF
Decrease
Inhibit angiogenesis
Human A549 lung cancer cells
2013
Xu et al. [119]
30
VEGF
Decrease
Inhibit angiogenesis
MCF-7 human mammary adenocarcinoma cells
2013
Dong et al. [120]
31
VEGF
Decrease
Inhibit angiogenesis
S180 sarcoma in mice
2014
Du et al. [121]
32
HIF-1
Decrease
Inhibit angiogenesis
Pancreatic cancer
2015
Singh et al. [122]
Sinomenine
33
VEGF
Decrease
Inhibit angiogenesis
Human synovial sarcoma cells (Hs701.T)
2006
Li et al. [123]
34
VEGF
Decrease
Inhibit angiogenesis
Umbilical vein endothelial cells (HUVEC) and U2OS cells
2016
Xie et al. [124]
Taspine
35
VEGF
Decrease
Inhibit angiogenesis
Chicken chorioallantoic membrane (CAM) neovascularization model and CAM transplantation tumor model
2008
Zhang et al. [125]
36
VEGF
Decrease
Inhibit angiogenesis
Human umbilical vein endothelial cells
2008
Zhao et al. [126]
37
VEGF
Decrease
Inhibit angiogenesis
Human umbilical vein endothelial cells
2010
Zhang et al. [127]
38
VEGF
Decrease
Inhibit angiogenesis
Caco-2 cell lines
2011
Zhang et al. [128]
39
VEGF
Decrease
Inhibit angiogenesis
Human liver cancer SMMC7721
2011
Zhang et al. [129]
40
VEGF
Decrease
Inhibit angiogenesis
Chicken chorioallantoic membrane (CAM) and mouse colon tissue
2012
Zhang et al. [130]
41
VEGF
Decrease
Inhibit angiogenesis
Human cell lines of SMMC-7721, A549, MCF-7, Lovo, and ECV304
2012
Zheng et al. [131]
42
VEGF
Decrease
Inhibit angiogenesis
A549 cells lung cancer
2012
Lu et al. [132]
Tetrandrine
43
PDGF
Decrease
Inhibit angiogenesis
Adjuvant-induced chronic inflammation model of mouse
1998
Kobayashi et al. [133]
44
VEGF
Decrease
Inhibit angiogenesis
RT-2 glioma RT
2009
Chen et al. [134]
45
HIF-1VEGF
Decrease
Inhibit angiogenesis
A rat model corneal neovascularization (CNV)
2011
Sun et al. [135]
46
HIF-1VEGF
Decrease
Inhibit angiogenesis
4T1 tumor bearing mice
2013
Gao et al. [136]
47
—
—
Inhibit angiogenesis
Human umbilical vein endothelial cells (HUVECs) and the human colon cancer cell line Lovo
2013
Qian et al. [137]
48
—
—
Inhibit angiogenesis
Liver cancer xenograft model in nude mice
2015
Xiao et al. [138]
Brucine
49
VEGFTGF-β
Decrease
Inhibit angiogenesis
Murine cannulated sponge implant angiogenesis model
2011
Agrawal et al. [139]
50
VEGF
Decrease
Inhibit angiogenesis
Ehrlich ascites tumor and human cancer cell line
2011
Agrawal et al. [140]
51
VEGF
Decrease
Inhibit angiogenesis
Nude mouse model of bone metastasis due to breast cancer
2012
Li et al. [141]
52
HIF-1
Decrease
Migration and metastasis and angiogenesis
Hepatocellular carcinoma
2013
Shu et al. [142]
53
VEGF
Decrease
Angiogenesis
Colon cancer cells
2013
Luo et al. [143]
54
VEGF
Decrease
Inhibit angiogenesis
Lovo cell
2013
Zheng et al. [144]
55
VEGF
Decrease
Inhibit angiogenesis
R breast cancer cell line MDA-MB-231
2013
Kechun and Zjauma [145]
Evodiamine
56
VEGF
Decrease
Inhibit angiogenesis
Human lung adenocarcinoma cell (CL1 cells)
2006
Shyu et al. [146]
57
VEGF
Decrease
Inhibit angiogenesis
Breast cancer cell
2008
Wang et al. [147]
58
HIF
Decrease
Inhibit angiogenesis
Human colon cancer cell
2015
Huang et al. [148]
Homoharringtonine
59
VEGF
Decrease
Inhibit angiogenesis
Human umbilical vein endothelial cell line (ECV304)
2004
Ye and Lin [149]
60
VEGF
Decrease
Inhibit angiogenesis
Leukemic cell line (K562) in vitro
2004
Ye and Lin [149]
61
VEGF
Decrease
Inhibit angiogenesis
Myeloid leukemia cells
2005
Fei and Zhang [150]
62
HIF
Decrease
Inhibit angiogenesis
K562 cell
2008
Li et al. [151]
Matrine
63
VEGF
Decrease
Inhibit angiogenesis
Breast cancer cell
2009
Yu et al. [152]
Halofuginone
64
VEGFMMP
Decrease
Inhibit angiogenesis
BALB/cν/ν (nude) mice
2003
Gross et al. [153]
65
—
—
Inhibit angiogenesis
Metastatic rat brain tumor model
2004
Abramovitch et al. [154]
66
TGF
Decrease
Inhibit angiogenesis
Polyoma middle T antigen mouse
2005
Yee et al. [155]
67
TGF-β-1, bFGF, COL1A1, MMP-2, MMP-9, VEGF, and PDGF
Decrease
Inhibit angiogenesis
Xenografted (rat)
2012
Jordan and Zeplin [156]
68
VEGFMMPTGF-β
Decrease
Inhibit angiogenesis
Acute promyelocytic leukemia mouse model
2015
Assis et al. [157]
Capsaicine
69
VEGF
Decrease
Inhibit angiogenesis
Endothelial cells in the rat aorta
2008
Pyun et al. [158]
70
VEGF
Decrease
Inhibit angiogenesis
Non-small-cell lung cancer
2014
Chakraborty et al. [159]
Pterogynidine
71
—
—
Inhibit angiogenesis
Human umbilical vein endothelial cells (HUVEC)
2009
Lopes et al. [160]Almost all alkaloids show an antiproliferative and cytotoxic activity against cancer cell lines derived from several different histological origins (esophagus, stomach, colon, liver, lung, breast, bone, and brain), and this activity depends also on the activation of the expression of apoptotic genes [161]. On the other hand, in vitro studies showed that antiangiogenic effects rely on some shared ability to downregulate, in the same cancer cells, VEGF, TNF-α, and HIF-1α messengers and/or proteins levels (with mechanisms ranging from low expression and higher degradation), blocking the angiogenic cascade in endothelial cells, as shown for berberine [102, 106], noscapine [97], brucine [140], evodiamine [146], homoharringtonine [149], matrine [162], and tetrandrine [136]. For instance, studies have shown that the cascade is blocked by matrine and tetrandrine at the levels of STAT3 signaling ([163] and [164], respectively), while evodiamine inhibits β-catenin [165]. Similar results were reported for sanguinarine, capsaicin, taspine, harmine, and pterogynidine, for whose deeper dissection of the molecular pathways demonstrated that antiangiogenic activities specifically involve Akt phosphorylation [138, 166, 167], CDK expression [168], and NF-κB translocation [160, 169] and that the effect is dose-dependent (10-300 nM) [166]. Other studies indicate that some alkaloids (sinomenine, brucine, and halofuginone) are able to directly regulate in vitro, at μM concentrations, and in vivo in transplanted mice, the expression of angiogenic factors ([123, 140] and [170], respectively). In particular, sinomenine and halofuginone should be able to induce Smad protein depletion ([157, 171]).Even if Ning et al. found that tetrandrine modulated, in human hypertrophic scar fibroblasts, the expression of miRNAs predicted to be related to wound healing [172], a process that is tightly related with angiogenesis [173], very little data is available at the moment on the role of miRNAs in alkaloid-associated angiogenic processes. One exception is for berberine that was shown to promote angiogenesis directly through miR-29b upregulation, upon induction of ischemia in mice [174]. The rest of the available data is restricted to experiments analyzing alkaloids as effectors of miR induction in different animal or cell models; for example, a recent study analyzed miRNA induction by berberine in porcine embryos [175]. Similarly, a berberine-containing commercially prepared traditional Chinese medicine Huang-Lian-Jiee-Dwu-Tang [176] was shown to induce VEGF and miR-126 expression in mesenchymal stem cell exosomes [177]. Interestingly, a recent paper suggests that berberine, together with evodiamine, is able to affect not only the expression of some miRs in colorectal cancer cells (in particular miR-29a) but also the expression of DNA methyltransferases that in turn regulate miRs’ activities, providing evidence for epigenetic activities of alkaloids during carcinogenesis [178]. In other searches, the pulmonary arterial hypertension- (PAH-) inducing plant pyrrolizidine alkaloid monocrotaline was shown to affect miR-21 and let-7a expression in the lung of monocrotaline-injected rats [179]. The role of miR-21 in PAH was later confirmed in humans [180], but no data is available on miR-21’s role on monocrotaline effects. Nonetheless, downregulation of miR-21, followed by the dephosphorylation of its target Akt, was reported also by the growth-inhibiting alkaloid matrine, on breast cancer cells [181]. Similar involvement of miR-21 by alkaloids was observed on human thyroid cancer cells [182], while other miRs were involved in other cells, i.e., miR-19b in melanoma [183], miR-106b in human acute T-cell lymphoblastic leukemia [184], and miR-126 in non-small-cell lung cancer [185].Kaymaz et al. found that Capsaicin strongly reduced miR-520a expression in chronic myeloid leukemia cells [186]. As the regulation is associated with the inhibition of cell proliferation, the authors hypothesized that alkaloid’s apoptotic properties could rely directly on miR-520a-5p/STAT3 interaction [186]. Similarly, data on rat hepatic stellate T6 cells suggest that the ability of sanguinarine to induce apoptosis through BCL2 downregulation could rely on the activation of miR-15a/16-1 expression [187]. On the other hand, homoharringtonine antileukemic effects were causatively related, by ectopic expression, to the activation of miR-370 and its target FoxM1, a major regulator in cell proliferation and apoptosis [188]. Other transfection experiments with miR mimics demonstrated unequivocally that inhibitory activities on invasion and metastasis by sinomenine on breast cancer cells depend on miR-324-5p and involve downstream NF-κB [189].


## 6. Conclusion

Based on data reviewed here and their ability to act as regulatory agents, alkaloids from natural sources are promising molecules with an enormous potential for therapeutic intervention of many disorders. Compounds from natural sources are believed to be good candidates for the prevention of angiogenic disorders and also as complements for chemotherapy or radiotherapy, in combination with other anticancer therapies [50, 190–192]. Berberine, noscapine, sanguinarine, and taspine among others are the most interesting and promising angiogenesis inhibitors. Further investigations are still required to elucidate their precise molecular and cellular mechanisms, as well as any potential side effects.



---

*Source: 9475908-2019-04-21.xml*